EUVIMEDEUVIMED entdecken
Open Access

Hepatobiliary Adverse Events Associated With Avacopan: Analysis of the JADER Database

Masaki Fujiwara, Kazumasa Kotake, Yuki Uemichi, Tadashi Shimizu

In Vivo · 2026-11 · 40 (6) · 3716-3724

DOI: 10.21873/invivo.14510 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, online erschienen am 29.10.2026. Verfasst von Masaki Fujiwara und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hyogo Medical University, Hyogo, Japan. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Liver Diseases, Chemical and Drug Induced Liver Injury. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Avacopan, a selective C5a receptor antagonist approved for anti-neutrophil cytoplasmic antibody-associated vasculitis, has been associated with hepatobiliary disorders including vanishing bile duct syndrome (VBDS). These events have been reported more frequently in Japanese patients than in Western populations. To address this population-specific safety concern, we characterized the reporting patterns of avacopan-associated hepatobiliary disorders using the Japanese Adverse Drug Event Report (JADER) database. PATIENTS AND METHODS: We analyzed reports submitted to JADER between April 2004 and January 2026 in which avacopan was registered as a suspect drug. Hepatobiliary adverse events were defined as a composite set comprising preferred terms (PTs) under the System Organ Class (SOC) "Hepatobiliary disorders" (code 10019805) of Medical Dictionary for Regulatory Activities (MedDRA)/J version 29.0 and two liver-related PTs classified under the SOC "Investigations" (code 10022891): Liver function test increased (10077692) and hepatic enzymes increased (10060795). Disproportionality was assessed using the reporting odds ratio with 95% confidence intervals (CIs); a signal was defined as three or more reports with a lower CI limit exceeding 1.0. Time to onset was calculated from treatment start to hepatobiliary adverse events onset, and post-event outcomes were categorized based on available JADER outcome data. RESULTS: Among 685 avacopan-related reports, disproportionality signals were detected for all hepatobiliary adverse events evaluated. The median time to onset of hepatobiliary adverse events ranged from 33 to 56.5 days, with most events occurring within one to two months after avacopan treatment. Of 226 reports with outcome data, 19 (8.4%) recorded death. Notably, 13 of 27 VBDS reports (48.1%) recorded death as the outcome, a markedly higher proportion than that for other hepatobiliary adverse events. CONCLUSION: These findings support the importance of continued post-marketing surveillance and monitoring of hepatobiliary events during avacopan treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Related Side Effects and Adverse ReactionsLiver DiseasesChemical and Drug Induced Liver InjuryHumansAdverse Drug Reaction Reporting SystemsDatabases, FactualFemaleMaleJapanMiddle AgedAged

Stichwörter der Autor:innen

ANCA-associated vasculitisAvacopanJADERJapanhepatobiliary disorderspharmacovigilance

Autor:innen und Institutionen

  • School of Pharmacy, Hyogo Medical University, Hyogo, Japan.
  • Department of Pharmacy, Zikei Hospital/Zikei Institute of Psychiatry, Okayama, Japan kottanketty@gmail.com.

Zitieren

APA

Fujiwara, M., Kotake, K., Uemichi, Y., & Shimizu, T. (2026). Hepatobiliary Adverse Events Associated With Avacopan: Analysis of the JADER Database. In Vivo, 40(6), 3716-3724. https://doi.org/10.21873/invivo.14510

Vancouver

Fujiwara M, Kotake K, Uemichi Y, Shimizu T. Hepatobiliary Adverse Events Associated With Avacopan: Analysis of the JADER Database. In Vivo. 2026;40(6):3716-3724. doi:10.21873/invivo.14510

BibTeX
@article{Fujiwara2026,
  author = {Fujiwara, Masaki and Kotake, Kazumasa and Uemichi, Yuki and Shimizu, Tadashi},
  title = {Hepatobiliary Adverse Events Associated With Avacopan: Analysis of the JADER Database},
  journal = {In Vivo},
  year = {2026},
  volume = {40},
  number = {6},
  pages = {3716--3724},
  doi = {10.21873/invivo.14510}
}
Kostenlos starten →